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Abstract
There are likely many scenarios and pathways that can lead to metabolic syndrome. This paper
reviews mechanisms by which the accumulation of visceral adipose tissue (VAT) may contribute to
the metabolic syndrome, and explores the paradigm of a critical VAT threshold (CVATT).
Exceeding the CVATT may result in a number of metabolic disturbances such as insulin resistance
to glucose uptake by cells. Metabolic profiles of patients with visceral obesity may substantially
improve after only modest weight loss. This could reflect a significant reduction in the amount of
VAT relative to peripheral or subcutaneous fat depots, thereby maintaining VAT below the
CVATT. The CVATT may be unique for each individual. This may help explain the phenomena of
apparently lean individuals with metabolic syndrome, the so-called metabolically normal weight
(MONW), as well as the obese with normal metabolic profiles, i.e., metabolically normal obese
(MNO), and those who are "fit and fat." The concept of CVATT may have implications for
prevention and treatment of metabolic syndrome, which may include controlling dietary
carbohydrates. The identification of the CVATT is admittedly difficult and its anatomical boundaries
are not well-defined. Thus, the CVATT will continue to be a work in progress.
Introduction
Arguably, the major pathogenic factor in the metabolic
syndrome is central obesity [1,2]. While abdominal obes-
ity is determined by the accumulation of both subcutane-
ous adipose tissue (SCAT) and visceral adipose tissue
(VAT), the excess accumulation of VAT appears to play a
more significant pathogenic role. VAT depots, located in
the body cavity beneath the abdominal muscles, are com-
posed of the greater and lesser omentum (peritoneum
that is attached to the stomach and links it with other
abdominal organs) and the mesenteric fat. A lesser
amount of VAT is located retroperitoneally. In general,
VAT accounts for up to 20 percent of total fat in men and
5–8 percent in women. The abdominal SCAT is located
immediately beneath the skin and on top of the abdomi-
nal musculature. The predominance of lower body fat is
SCAT, most of which is stored in the femoral and gluteal
regions [3-5]. Abdominal obesity can reflect a predomi-
nance of flabby SCAT; a firm, only modestly enlarged
waist line resulting from deep VAT pushing the abdomi-
nal musculature outward; or a combination of enlarged
SCAT and VAT depots. With the advent of more precise
imaging techniques, e.g., magnetic resonance imaging
(MRI) [6], computed tomography (CT) [7], and ultra-
sound [8], it has become evident that the accumulation of
VAT not only accompanies but antedates the onset of the
Published: 05 November 2004
Nutrition & Metabolism 2004, 1:12 doi:10.1186/1743-7075-1-12
Received: 20 September 2004
Accepted: 05 November 2004
This article is available from: http://www.nutritionandmetabolism.com/content/1/1/12
© 2004 Freedland; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Nutrition & Metabolism 2004, 1:12 http://www.nutritionandmetabolism.com/content/1/1/12
Page 2 of 24
(page number not for citation purposes)
components of the metabolic syndrome and related disor-
ders, e.g., insulin resistance, hypertension [9], glucose
intolerance [10], type 2 diabetes, and coronary heart dis-
ease [11].
To date, it has not yet been established that insulin resist-
ance, i.e., resistance of cells to insulin's effects, is respon-
sible for the onset of the multiple risk factors associated
with insulin resistance syndrome and subsequent devel-
opment of atherosclerosis and cardiac events [12]. In fact,
National Cholesterol Education Program Adult Treatment
Panel (ATP III) criteria for Metabolic Syndrome have been
found to have a low sensitivity for predicting insulin
resistance [13-15] and may be better thought of as predic-
tors for cardiovascular risk [16]. In a recent study of a large
number of apparently healthy men and women of varying
age, VAT area was significantly associated with all of the
metabolic syndrome criteria as defined by the NCEP ATP
III. This was independent of insulin sensitivity and SCAT
area. Insulin sensitivity was found to be independently
associated with the criteria for HDL cholesterol, triglycer-
ides (TGs), and fasting plasma glucose (FPG). SCAT area
was independently correlated with only waist circumfer-
ence after adjusting for VAT area and insulin sensitivity
[11]. In addition, the study results showed that clinical
assessments of increased waist size and TG levels are
strongly associated with decreased insulin sensitivity and
increased VAT in individuals with fasting FPG <6.4 mmol/
L [11].
The term "metabolic syndrome" is now preferable to
"insulin resistance syndrome," and has a prevalence of 25
percent in U.S. individuals age >20, rising to >40 percent
by age 60 [17]. The importance of central obesity is well-
recognized in the definitions of metabolic syndrome [18]
per the American College of Endocrinology, [19,20]
National Cholesterol Education Program Adult Treatment
Panel (ATP III), [21] European Group for the Study of
Insulin Resistance, [22] and World Health Organization
(WHO) [23]. However, even apparently lean individuals
with normal BMIs can have a significant accumulation of
VAT with increased risk factors for cardiovascular disease
and diabetes (metabolically obese normal weight;
MONW) [24-26]. Meanwhile, obese individuals with
large BMIs but relatively little VAT can present with nor-
mal metabolic profiles and a paucity of risk factors for
metabolic syndrome, cardiovascular disease, and diabe-
tes, i.e., the metabolically normal obese; MNO) [5,27].
Ectopic Fat Storage Syndrome
The ectopic fat storage syndrome hypothesis suggests that as
adipocytes hypertrophy and reach their capacity for stor-
ing more fat, then additional fat from excess dietary lipids
or calories is deferred to non-adipose tissues intracellu-
larly, e.g. liver, skeletal muscle, heart, and the beta cells of
the pancreas where they can exert toxic effects and dys-
function [7]. This "lipotoxicity" may also be exacerbated
by impaired oxidation of fat within tissues [7,28-30]. Fur-
thermore, adipose tissue is a major endocrine organ that
secretes numerous polypeptide hormones and cytokines
that are proinflammatory and proatherogenic. These play
a major role in affecting insulin action in skeletal muscle
and creating a low-grade state of inflammation and
endothelial dysfunction [31]. Compared to SCAT, VAT
has been correlated more with endothelial dysfunction
[32,33].
CVATT – A Working Hypothesis
It must be emphasized that the current proposal is a work-
ing hypothesis. Figure 1 describes a critical VAT threshold
(CVATT) which is unique for a given individual and rep-
resents a range for the accumulation of a critical mass of
VAT (CVATT) that when achieved, leads to the develop-
ment of metabolic syndrome. Note that insulin sensitivity
is important for weight gain [34] and accumulation of
VAT, and investigators have proposed that insulin resist-
ance may actually, to a certain extent, be beneficial by pro-
tecting cells with already impaired fatty acid oxidation.
Once the CVATT is reached, insulin resistance (IR) occurs,
which may be protective initially [29,35-37]. In addition
to protecting against further weight and fat gain [34,38-
41], insulin resistance prevents glucose and more fat from
entering the cell and becoming preferentially oxidized.
Hence, insulin resistance also allows intracellular fat
already present within the cell to become oxidized rather
than cause further damage through "lipotoxicity
[29,30,40,42,43]."
Implications of VAT loss
It is encouraging that only a modest loss of 5–10 percent
of body weight in obese patients is associated with prefer-
ential mobilization of VAT compared to SCAT, leading to
simultaneous improvement in all metabolic markers of
CHD risk. Such modest weight loss can prevent and
reverse type 2 diabetes [44-48], and sustained weight loss
in obese women results in a reduction in elevated inflam-
matory cytokine levels and an amelioration of endothelial
dysfunction [49,50]. Surgical removal of VAT may reduce
insulin resistance and plasma insulin levels [51,52], while
liposuction of SCAT does not confer metabolic benefits
[53]. Weight loss usually leads to VAT reduction as well as
reduction of depots of fat in non-adipose organs, thereby
improving insulin sensitivity [48]. However, once individ-
uals improve insulin sensitivity by losing weight and
crossing beneath their CVATT [48], they may now be
more susceptible to weight gain and struggle to maintain
this new state.
With total weight loss, those with greater amounts of VAT
initially lose more VAT, and VAT is more sensitive toNutrition & Metabolism 2004, 1:12 http://www.nutritionandmetabolism.com/content/1/1/12
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weight reduction because the VAT adipocyte is more met-
abolically active and sensitive to lipolysis [5,54]. After the
initial weight loss, further dietary restriction may lead to
an overall reduction in body fat, rather than specific loss
from a particular site. The metabolic improvements
observed with only modest reductions in total weight
underscore the importance of VAT in insulin resistance
and metabolic abnormalities [48,55]. Once the individual
has lost a significant amount of VAT and is now below his
CVATT, improvement in insulin sensitivity does not bear
a linear relationship to the magnitude of weight loss [48].
The identification of the CVATT is admittedly difficult and
its anatomical boundaries are not well-defined. Thus, the
CVATT will continue to be a work in progress. While there
are numerous studies linking VAT quantity to insulin
resistance and metabolic syndrome, this does not neces-
sarily prove that VAT is the cause. However, there are a
number of plausible mechanisms linking VAT to the met-
abolic syndrome.
Adipose tissue as an endocrine organ
Adipokines
Once thought to be an inert energy storage depot, adipose
tissue is now known to be a critical endocrine organ. The
term "adipocytokines" or "adipokines" has been used to
describe the numerous adipocyte secretory products
which include: adiponectin, adipsin, estrogen, angi-
otensin II, angiotensinogen, leptin, plasminogen activator
I (PAI-1), agouti protein, resistin [56], acylation stimulat-
ing protein (ASP), bone morphogenic protein (BMP),
prostaglandins, IGF-1, and various IGF binding proteins,
tumor necrosis factor alpha (TNFα), interleukins (ILs),
transforming growth factor (TGF)-B [57], and fibroblasts,
Critical Visceral Adipose Tissue Threshold (CVATT) Figure 1
Critical Visceral Adipose Tissue Threshold (CVATT). According to the hypothesis, there is an individual range for 
accumulating a critical amount of visceral adipose tissue (VAT). Insulin sensitivity is important for weight gain and accumulation 
of VAT. Once the critical VAT threshold (CVATT) is reached, insulin resistance occurs, which may be protective initially and 
impair further weight and fat gain. Continuation of VAT accumulation can lead to metabolic syndrome. However, only a mod-
est weight loss (5–10 percent) with accompanying VAT loss can reverse the process.
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as well as FFAs themselves. Adipokines such as IL-6 and
PAI-1 are more highly secreted by VAT than abdominal
SCAT [58,59], while leptin is more highly secreted by
SCAT [60]. Adipokines from VAT can be delivered via the
portal system directly to the liver where they can affect
hepatic, and ultimately systemic, inflammation. In an ex
vivo study, VAT released greater amount of IL-6 and PAI-1
compared with abdominal SCAT [58,61].
Adiponectin has many beneficial vascular and metabolic
effects, e.g., it serves as an anti-inflammatory molecule for
vascular walls as well as adipose tissue, inhibits vascular
smooth muscle proliferation, protects endothelium from
macrophage adhesion and macrophage-induced injury
[62], may increase fatty acid oxidation in peripheral tis-
sues [63], protects against ectopic fat storage and has been
linked with insulin sensitivity [64,65].
Ironically, although produced by adipose tissue, adi-
ponectin levels are lowered with greater degrees of obesity
and with overfeeding. Decreased concentrations of adi-
ponectin are associated with type 2 diabetes, hyperten-
sion, elevated glucose levels, insulin and TGs, and
cardiovascular disease (CVD). It has been suggested that
adiponectin is under feedback inhibition in obesity and
reduced in patients with metabolic syndrome [66]. Adi-
ponectin mRNA and protein levels have been found to be
reduced in omental VAT compared with SCAT [67], and
VAT may also produce an as-yet-identified factor that
destabilizes adiponectin mRNA [66,68]. The strong
inverse correlation between serum adiponectin levels and
VAT mass may in part explain the link between VAT and
metabolic syndrome [66]. Over 90 percent of the adipok-
ines released by adipose tissue, except for adiponectin and
leptin, could be attributed to non-fat cells, e.g., macro-
phages, retained in the adipose tissue matrix [61].
Implications of fat mass expansion
Fat mass can expand in one of two ways: individual adi-
pocytes can increase in volume or they can increase in
number as more are derived from preadipocytes. As adi-
pocytes grow larger, they become dysfunctional. The total
number of adipocytes is increased with increasing fat
mass, but it is the increased number and percentage of
large adipocytes, compared to the smaller ones, that may
partially account for the inability of adipose tissue to func-
tion properly [69]. While the smaller adipose cells tend to
be more insulin sensitive, large adipocytes become insulin
resistant and contribute more to the metabolic problems
associated with obesity [69].
Preadipocytes from the SCAT depots have a greater differ-
entiation capacity than those from the VAT depots
[70,71]. The differentiation of preadipocytes into lipid-
storing adipocytes is regulated in part by the nuclear hor-
mone receptor, peroxisome proliferators activated recep-
tor (PPAR). Activation of this receptor by natural ligands,
such as prostaglandin metabolites, or synthetic ligands,
such as thiazolidinediones (TZDs), leads to stimulation of
the differentiation pathway [71]. This increases the
number of smaller adipocytes in SCAT with a high avidity
for FA and TG uptake. These increased adipose stores
made up of new, smaller, more insulin sensitive adi-
pocytes act as a sink or powerful 'buffers,' avidly absorb-
ing circulating fatty acids and triglycerides in the
postprandial period. This prevents their diversion to non-
adipose tissues, thereby protecting against ectopic fat syn-
drome and metabolic syndrome. It has been proposed
that an inability to differentiate new adipocytes to accom-
modate and store excess energy, underlies the develop-
ment of type 2 diabetes [72,73].
A thiazolidinedione (TZD) paradox
TZDs can increase the number of new fat cells, and
because obesity is a major cause of insulin resistance, this
represents an apparent paradox. Ex-vivo studies of human
preadipocytes from SCAT and VAT depots have demon-
strated that TZD-stimulated differentiation is much
greater in SCAT than VAT preadipocytes [71]. Since TZDs
selectively promote adipogenesis in SCAT and not VAT,
this would encourage the redistribution of body fat away
from "harmful" VAT sites and toward "safer" SCAT ones
[74-76]. Thus, in this way, TZDs could allow for pushing
the patient to below his CVATT. Paradoxically, the TZDs
can lead to weight gain while improving insulin sensitiv-
ity as the new SCAT adipocytes continue to trap FA and as
fat storage continues, eventually the new adipocytes will
enlarge, become less insulin sensitive, and ultimately con-
tribute to insulin resistance [77]. TZDs may also exert anti-
inflammatory effects on adipocytes by reducing the pro-
duction of serum amyloid A (SAA) and preventing the
TNFα-mediated expression of adiponectin production
[69].
Adipose macrophages
Macrophages increase their accumulation within fat
depots in direct proportion to increases in adipose tissue
and adipocyte size. The increased macrophage activity
observed in the adipose tissue of the obese may reflect a
combination of conversion of local preadipocytes to mac-
rophages and activation and recruitment of resident mac-
rophages and circulating monocytes. This seems to occur
after the onset of adiposity but prior to insulin resistance,
and supports the notion that pathophysiological conse-
quences of obesity involve macrophages and inflamma-
tion that contribute to insulin resistance and metabolic
syndrome [78,79]. Evidence suggests that macrophages
and adipocytes not only express overlapping sets of genes
and serve similar functions, but also commingle in the
same part of the body – the fat tissue [80].Nutrition & Metabolism 2004, 1:12 http://www.nutritionandmetabolism.com/content/1/1/12
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VAT Versus SCAT (See figure 2)
VAT
There are numerous inherent differences between VAT
and SCAT. VAT is a major predictor for insulin resistance
[81] and metabolic syndrome [11]. Compared to SCAT,
VAT adipocytes have a higher rate of lipolysis, which is
more readily stimulated by catecholamines and less read-
ily suppressed by insulin [82]. VAT also produces more IL-
6 and plasminogen activator inhibitor-1 (PAI-1) [81]. The
"Portal Theory" suggests that insulin resistance and many
of its related features could arise from VAT delivering free
fatty acids (FFAs) at a high rate to the liver via the portal
vein into which VAT directly drains [83,84]. This, in turn,
would increase hepatic glucose production, reduce
hepatic insulin clearance, and ultimately lead to insulin
resistance, hyperinsulinemia, hyperglycemia as well as
non-alcoholic fatty liver disease (NAFLD). FFA flux could
also lead to enhanced production of triglycerides (TGs)
and apolipoprotein B-rich lipoproteins, which are fea-
tures of the insulin resistance syndrome [55,85]. Delivery
of VAT derived pro-inflammatory cytokines may contrib-
ute to hepatic pathology such as non-alcoholic steatohep-
atitis (NASH). VAT also releases a large amount of glycerol
which enters the liver where it can be converted to glu-
cose, thereby contributing to hyperglycemia [86]. It is
likely that the relationship observed between VAT and
metabolic complications may not exclusively result from
FFA flux from VAT into the portal vein and the portal the-
ory does not adequately hold up as the sole explanation
of the role of VAT in metabolic syndrome [7].
VAT has twice the glucose uptake rate as SCAT
Recently, omental VAT cells have been shown to have an
approximately two-fold higher rate of insulin-stimulated
glucose uptake compared with SCAT adipocytes, and this
could be explained by a higher GLUT-4 expression [87].
Perhaps in situations with a high intake of dietary glyc-
emic load, a higher rate of glucose uptake and subse-
quently lipogenesis might be one mechanism by which
TGs are stored preferentially in the VAT depot. VAT is
highly lipolytic and resistant to insulin's lipogenic effects
yet apparently can remain insulin sensitive to glucose
uptake. This efficiency in glucose uptake may reflect VAT's
ability to accumulate and maintain its activity. Enhanced
VAT versus SCAT Figure 2
VAT versus SCAT
VAT VAT vs vs SCAT SCAT
  Major predictor of IR /Metabolic Major predictor of IR /Metabolic
Syndrome Syndrome
  Less responsive to insulin Less responsive to insulin’ ’s s
adipogenic adipogenic effects effects
  More More lipolytic lipolytic
  Portal Drainage Portal Drainage
  May enhance  May enhance truncal truncal SCAT SCAT
lipolysis lipolysis
  Produces more IL Produces more IL- -6, PAI 6, PAI- -1 1
  More More glucocorticoid glucocorticoid receptors receptors
  High density of androgen receptors High density of androgen receptors
  Preadipocytes Preadipocytes have greater have greater
differentiation capacity differentiation capacity
  May replenish VAT May replenish VAT
  Estrogen promotes Estrogen promotes
  Produces Leptin Produces Leptin
  ? Role in IR ? Role in IR
  May be protective May be protectiveNutrition & Metabolism 2004, 1:12 http://www.nutritionandmetabolism.com/content/1/1/12
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glucose utilization in VAT would be accompanied by less
lipid oxidation, which would indirectly promote TG stor-
age [87].
Testosterone
VAT has a high density of androgen receptors and testo-
sterone which can amplify its own effect by up-regulation
of androgen receptors, inhibiting the expression of lipo-
protein lipase (LPL) and FA uptake [5,88]. In men, VAT is
strongly negatively correlated with plasma total and free
testosterone and sex-hormone binding globulin (SHBG)
concentrations. Thus, in young men whose plasma total
testosterone and free testosterone are high, the amount of
VAT is low. As men age, exceed their 20s, and reach mid-
dle age, their total and free testosterone decline, more fat
is deposited in VAT stores, they often develop the "pot
belly," and their risk for CHD increases [5,89]. The effects
of testosterone on insulin resistance and metabolic syn-
drome risk factors are opposite in men and women
[5,88,90,91]. Testosterone production often declines in
women as they age, but VAT obesity in women is associ-
ated with elevated levels of total testosterone, free testo-
sterone., and SHBG [92]. Hyperandrogenicity can also
occur in polycystic ovary syndrome, where hyperinsuline-
mia can stimulate ovarian androgen production and sup-
press serum SHBG [88,93]. While weight loss in both
sexes has been consistently shown to reverse the abnor-
malities in testosterone levels [94-97], a number of pla-
cebo controlled studies have consistently demonstrated
that administering testosterone to obese men resulted in a
significant reduction in VAT. This occurred without signif-
icantly altering amounts of total body fat or lean body
mass [89,98-100]. However, the use of testosterone for
VAT obesity is left open to debate [90].
11-β-Hydroxydehydrogenase1 (11-β HSD1)
Patients with type 2 diabetes and metabolic syndrome
often appear Cushingoid, yet they invariably do not have
elevated plasma cortisol [101]. Compared to SCAT, VAT
has more glucocorticoid receptors [88]. The enzyme 11-β
hydroxysteroid dehydrogenase type 1 (11-β HSD1) con-
verts inactive cortisone to the active compound cortisol,
and, if overexpressed, may cause increases in local cortisol
concentrations [101]. Local production of active cortisol
from inactive cortisone driven by 11-β-HSD-1 activity is
very high in VAT and barely detectable in SCAT. Therefore
it is likely that the VAT depot actively contributes to the
production of high local concentrations of cortisol, which
might not be reflected by plasma levels. These, in turn,
might contribute to an increase in VAT accumulation
[102]. 11-βHSD1 inhibition holds promise as a therapeu-
tic target for VAT-associated metabolic syndrome
[103,104].
VAT and impaired skeletal muscle oxidation
The amount of fat deposited within skeletal muscle
(intramyocellular lipid – IMCL) and the ability of muscle
to oxidize fat are important determinants of weight
gain,[105] weight regain following weight loss [106], and
the development of insulin resistance syndrome [107].
IMCL and the VAT depot might not be independent from
each other. Furthermore, the relationship between IMCL
and insulin sensitivity is independent of percent total
body fat and SCAT but not of VAT [108]. In individuals
with type 2 diabetes, among the depots of regional and
overall adiposity, VAT was the depot of adipose tissue that
was most strongly related to skeletal muscle insulin resist-
ance [109].
Colberg et al studied the fasting patterns of skeletal mus-
cle fatty acid uptake and oxidation in healthy, lean and
obese premenopausal women who had a cross-sectional
VAT area over a range from 18 to 180 cm2 and BMIs from
19 to 39 kg/m2 [110]. The researchers found that insulin
sensitivity as well as postabsorptive rates of FFA utiliza-
tion or oxidation by muscle were diminished in relation
to VAT. Women with increased VAT did not have lower
plasma FFA levels or lower rates for appearance of FFA, yet
they had an impaired or reduced uptake of plasma FFA by
the skeletal muscle in the leg [111]. Together, this sup-
ports a role for VAT, IMCL lipid deposition, and perhaps
impaired oxidation of nonadipose tissue lipid in insulin
resistance and metabolic syndrome.
VAT may influence central SCAT
Mauriege et al found that adrenoreceptor sensitivity was
increased in SCAT cells of individuals who have a higher
VAT accumulation compared to those with a low VAT dep-
osition [112]. SCAT adipocytes from women with visceral
obesity exhibit higher lipolysis rates in vitro than those
obtained from women with little VAT [113]. Mauriege et
al also demonstrated that among men with high levels of
VAT, SCAT adipocytes are more sensitive to β-adrenergic
lipolysis which may further exacerbate an impaired insu-
lin action, a potentially important factor in the etiology of
metabolic syndrome associated with visceral obesity
[112]. Moreover, an increased truncal SCAT mass and an
increased amount of VAT mass can independently predict
insulin resistance [114]. Together, these findings support
that VAT may enhance central SCAT lipolysis and acceler-
ate release of peripheral FFAs.
The PPARs are important transcription factors that play an
important role in the induction of adipose-specific genes,
the proliferation and differentiation of adipocytes, and
the development of mature adipose tissue. A number of
transcription factors are involved, including PPARγs.
Giusti et al suggest that in VAT, the expression of PPARγ2
is controlled by local transcription factors (RXRα,Nutrition & Metabolism 2004, 1:12 http://www.nutritionandmetabolism.com/content/1/1/12
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αSREBP1, and SREBP1c) promoting fat storage in adi-
pocytes. Given that the fat storage capacity is limited in
VAT, RXRα induces the expression of PPARγ2 in SCAT to
increase its overall capacity [115]. These data also suggest
that the signal to promote fat storage may occur in VAT
and that other metabolic and hormonal factors are
involved in the control and modulation of adipogenesis
in visceral fat [115].
Perhaps the above can be explained as follows. SCAT cells
may act as a buffer or sink for circulating FAs and TGs but
once they reach their capacity they lose their protective
benefits. Initially, VAT may influence SCAT to expand and
act as a buffer. However, once the critical VAT threshold
(CVATT) is achieved and metabolic syndrome has begun
to develop, then VAT may influence central SCAT to
become more VAT-like, i.e., more lipolytic and less sensi-
tive to insulin's adipogenic or lipid storing effects.
SCAT
Greater preadipocyte differentiation and protection
As discussed earlier, preadipocytes from SCAT depots
have a greater capacity than VAT to differentiate into
numerous, small, insulin-sensitive, adipocytes [70,71].
These lipid-storing cells act as a buffer or sink for circulat-
ing FAs and TGs, thereby preventing their deposition in
non-adipose tissues, e.g., skeletal muscle, pancreas, and
liver, where they could contribute to lipotoxicity, apopto-
sis, and insulin resistance [73,116].
Does SCAT replenish VAT?
In defending the role of VAT accumulation in individuals
with metabolic syndrome, we must postulate a high rate
of lipid turnover, with high rates of lipolysis at certain
times matched by high rates of lipid deposition at other
times. Otherwise, as Frayn points out, the hyperlipolytic
VAT would ultimately disappear [117]. He also suggests
that if SCAT were to become insulin resistant, and there-
fore resistant to fat storage, then fat might tend to be
deposited in VAT depots. Another possibility is that the
usually larger SCAT depot has a greater potential to con-
tribute to insulin resistance through release of FFA into
the systemic circulation. However, this would not ade-
quately explain the subset of individuals who demon-
strate metabolic profiles consistent with insulin resistance
but are in fact lean, healthy-appearing with normal BMIs,
excess VAT, little SCAT, and are referred to as "metaboli-
cally obese, normal weight (MONW) [26]. As described
above, perhaps once VAT expands and SCAT depots reach
their capacity for storing FAs, then do SCAT adipocytes
become insulin resistant, release FFAs, and contribute to
systemic insulin resistance and metabolic syndrome.
While some studies cast doubt on the portal theory and its
implications for VAT's direct delivery of FFA to the liver
[118,119], they leave open other mechanisms via which
VAT could induce insulin resistance and other metabolic
disturbances, e.g., by producing proinflammatory
cytokines which could be directly delivered to the liver
where they can potentially affect hepatic metabolism
[117]. These will be discussed below.
Peripheral fat mass may protect against atherosclerosis and 
metabolic syndrome
If trunk fat is taken into account, accumulation of fat in
the hips and legs is an independent predictor of lower car-
diovascular and diabetes-related mortality, and it seems to
protect against impaired glucose metabolism, especially
in women [120-124]. In a study of 1,356 women ages 60–
85, those with excessive peripheral fat had less atheroscle-
rosis (determined by aortic calcification scores), and the
quartile with both the highest amount of central fat and
peripheral fat seemed to be partially protected by the high
percentage of peripheral fat mass as reflected in a number
of measured risk factors [121]. These findings corroborate
similar findings by the same group who followed 316
postmenopausal women for 7.7 years and monitored pro-
gression of aortic calcifications [120]. In yet another
study, Tanko et al demonstrated that peripheral fat mass
(SCAT) in generally obese, post-menopausal women is
associated with increased adiponectin and higher insulin
sensitivity [125]. Together, these support protective roles
for peripheral fat. In addition to fat trapping, these might
include possible influences on adipokines, e.g., they
might contribute to an increase in adiponectin, which
could improve FA oxidation [126]. One must interpret
these results with caution because the measuring tech-
nique of dual-energy X-ray absorptiometry (DXA) does
not allow separate quantification of intermuscular and
subcutaneous fat in the arms and legs as well as SCAT in
the trunk [121]. While VAT is a major predictor of insulin
sensitivity in overweight and lean individuals [114,127],
others have found abdominal SCAT to contribute to insu-
lin resistance independently of VAT [128,129].
An example of metabolically innocent obesity
When there is an inability to store fat, due to lipodystro-
phy, the adipocytes' storage capacity is exceeded and lip-
ids accumulate and cause lipotoxicity in liver, muscle, and
other organ tissues [7]. A counterpart of lipodystrophy
may be illustrated by patients with multiple symmetric
lipomatosis (MSL), a condition characterized by regional
excess of subcutaneous adipose tissue. These patients have
higher adiponectin levels, a high degree of insulin sensi-
tivity and glucose tolerance, very low lipid levels in liver
and muscle cells, and markedly little VAT [130]. In this
case, SCAT may be protective and beneficial. This may be
analogous to thiazolidinedione action, which also pro-
motes SCAT deposition while improving insulin sensitiv-
ity and glucose tolerance [74,75].Nutrition & Metabolism 2004, 1:12 http://www.nutritionandmetabolism.com/content/1/1/12
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Estrogen
Estrogen promotes the accumulation of peripheral gluteo-
femoral SCAT, which may be protective [131]. The
abundant presence of peripheral fat mass in generally
obese women is associated with increased plasma adi-
ponectin, and the loss of estrogen with menopause is
associated with an increase in central fat [132]. This
accounts for the progression in many overweight women
after menopause from a predominantly pear-shape or
"gynoid" habitus to the apple or "android" shape. Con-
trary to popular belief, menopause does not seem to inde-
pendently cause a gain in total body weight; the increases
in BMI that often accompany menopause are usually con-
sistent with normal aging [133]. However, even without
weight gain, body fat distribution changes; postmenopau-
sal obese women tend to accumulate abdominal fat along
with deterioration of risk factors, even if total body weight
and BMI do not change during menopause transition.
After menopause, when ovarian function declines, adi-
pocytes become the primary source of endogenous estro-
gens [134], and compared to "gynoid" or pear-shaped
women, those with central obesity (apple- or "android-"
shaped) have lower plasma SHBG and higher estradiol
[125,135]. This suggests regional differences in the enzy-
matic conversion of steroid hormones in VAT versus SCAT
[125,136-138]. In ovarian hormone-deficient women,
SCAT adipocyte size, lipoprotein lipase (LPL) activity, and
basal lipolysis were not found to be significantly greater
compared to regularly cycling premenopausal women.
However, in the ovarian hormone-deficient women,
omental (VAT) adipocyte size was significantly higher,
and the omental/SCAT LPL activity ratio and VAT lipolysis
were also significantly higher [139]. For a given amount of
total body fat, men have been found to have about twice
the amount of VAT than what is found in premenopausal
women but this may change after menopause when VAT
storage becomes predominant [140,141].
Along with an increase in VAT, a decline in estrogen is also
associated with reduced lean body mass as well as other
features of the metabolic syndrome including: dyslipi-
demia with elevation in Lp(a), triglycerides, and an
increase in small, dense, LDL particles. Estrogen defi-
ciency also may influence cardiac risk by its effects on the
insulin action, the arterial wall, and fibrinolysis. Park et al
showed that postmenopausal women lost less VAT com-
pared with the premenopausal women during a weight
reduction program (10.5 percent vs. 25.7 percent respec-
tively) [142]. The reasons behind this are presently
unclear.
As mentioned above, in menopause, adipocytes are pri-
mary sources of endogenous estrogens in women
[125,134], and estrogens are known inhibitors of IL-6
secretion [143]. It is worth noting that the relationship
between BMI and serum IL-6 was observed only in post-
menopausal women, and this relationship was lost
among those women receiving hormone replacement
[144]. Adipose tissue-derived estrogens in postmenopau-
sal women would not be sufficient to reduce IL-6 in a sim-
ilar way as endogenous estrogens do in premenopausal
women [145]. Perhaps in premenopausal women, endog-
enous estrogen from the ovaries helps keep VAT volume
relatively low and is thereby protective. Estrogen by itself
seems to protect postmenopausal women receiving
replacement therapy from VAT accumulation, and in
women with type 2 diabetes, estrogen replacement may
protect against the risk of cardiac events [146,147].
Compared to men of similar age, premenopausal women
appear to be significantly protected from CHD. However,
by age 70 the incidence of CHD is equal in men and
women, suggesting that estrogen deficiency causes a rapid
acceleration in CHD risk [133]. Yet, in elderly, postmeno-
pausal women, Tanko et al showed that those women
with higher amounts of central versus peripheral obesity
had significantly higher levels of estradiol and lower adi-
ponectin. This suggests that prolonged and increased
exposure of SCAT cells to estradiol may eliminate the pro-
tective effect of SCAT by affecting SCAT's ability to release
adiponectin thereby promoting the atherogenic effects of
IL-6 [125]. Perhaps future research will help clarify
whether central obesity has any implication for increased
susceptibility to the adverse cardiovascular effects of hor-
mone replacement therapy (HRT) in diabetic patients
early after initiation of therapy [125].
Obesity, particularly visceral obesity, as well as insulin
resistance and hyperinsulinemia are associated with
breast cancer [148]. Insulin may increase estrogen action
by increasing bioavailable estrogen due to a decrease in
sex hormone-binding globulin, by influencing estrogen
receptors, and by increasing aromatization of androgen to
estrogen at the tissue level, a phenomenon which has
been demonstrated in breast tissue. Estrogen upregulates
the IGF-1 receptor and IGFBP-1 and -2 and may directly
activate the IGF-1 receptor, thereby increasing insulin sig-
naling [149].
Around 1900, most women died soon after menopause.
The average lifespan of persons in the United States has
since lengthened by greater than 30 years [150], which
means that women, and men, too, are now spending 30
or more years with hormonal and physiological states that
society and medicine has not had to deal with previously.
These, combined with significant dietary and lifestyle
changes since 1900, must be considered as critical contrib-
uting factors to the world's current epidemic of metabolic
syndrome.Nutrition & Metabolism 2004, 1:12 http://www.nutritionandmetabolism.com/content/1/1/12
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Lipotoxicity Model
Overnutrition, lipotoxicity, leptin, and the metabolic syndrome
When one consumes too many calories, especially in the
form of excessive carbohydrates, the liver converts excess
glucose to fatty acids. First, glucose that is not oxidized or
stored as glycogen is metabolized to acetyl CoA, which
then enters the lipogenic pathway. Acetyl CoA is catalyzed
to form malonyl CoA, which in turn inhibits carnitine
palmitoyl transferase 1 (CPT-1, the enzyme responsible
for fatty acid transport into the mitochondria) [42]. The
net effect is that malonyl CoA (from excess carbohydrates,
glucose, and insulin) reduces the oxidation of FAs [151].
This results in increased accumulation of intracellular fat
in the form of long chain fatty acids and their derivatives,
e.g., TGs and ceramide [28,29]. Cellular TG accumulation
is not initially toxic and may actually be protective by
diverting excess FAs from pathways that lead to cytotoxic-
ity [152]. While glucose is being preferentially utilized,
the FAs are metabolized by pathways other than their pre-
ferred β oxidation, leading to toxic products, e.g., cera-
mide, which may cause apoptosis and lipotoxicity
[28,30,153]. The subsequent development of the cell's
resistance to insulin-mediated glucose uptake, which pre-
vents further influx of glucose, may be viewed as being
protective in that it limits the amount of intracellular glu-
cose to be preferentially metabolized over the β oxidation
of intracellular FAs [29,37,154]. The cell can be insulin
resistant with respect to glucose uptake and metabolism
but remain sensitive to insulin's lipogenic effects and the
de novo synthesis of fat. Overconsumption of calories,
especially in the form of carbohydrates, also stimulates
hyperinsulinemia that can then upregulate SREBP-1c and
increase de novo lipogenesis [43].
Leptin protects against lipotoxicity
Leptin
The first adipocyte-specific hormone to be characterized,
leptin is produced predominantly by SCAT adipocytes
compared to VAT. Females produce leptin at about twice
the rate in males [155], and leptin secretion increases with
enlarged adipocyte cell size. Circulating leptin rises by 40
percent after acute overfeeding and more than three-fold
after chronic overfeeding, whereas fasting is associated
with decreased leptin levels [156].
Dietary carbohydrates may influence leptin action
The increase in leptin concentration after meals is not sim-
ply a result of a caloric load, but is in response to a signal
that is not present following a fat load without carbohy-
drate [157]. Leptin circulates in a free form and is also
bound to a soluble leptin receptor – sOBR, which is posi-
tively associated with energy intake from carbohydrates
and negatively associated with energy intake from dietary
fat [158].
Excess caloric consumption and fat deposition results in
newly synthesized FAs that are transported as VLDLs and
stored as TG in adipocytes. Initially, these expanding adi-
pocytes secrete leptin in proportion to their growing fat
accumulation. Leptin also crosses the blood brain barrier,
stimulates its receptor in the hypothalamus, and causes
the release of neuropeptide-Y (NP-Y), which reduces feed-
ing behavior [85]. This, in turn, suppresses appetite and
stimulates thyroid function. Leptin affects peripheral tis-
sues, and is a determinant of insulin sensitivity. The ensu-
ing hyperleptinemia increases fat oxidation in skeletal
muscle [159-161], and also keeps de novo lipogenesis in
check by lowering the involved transcription factor, i.e.,
SREBP-1c mRNA (sterol regulatory element binding pro-
tein 1c mRNA) [43]. It promotes cholesterol ester synthe-
sis in macrophages in a hyperglycemic environment, an
important process in the formation of foam cells in
atherosclerosis which may suggest a protective role of rel-
ative leptin resistance [162]. Leptin also possibly increases
sympathetic nervous system (SNS) activity with subse-
quent decreased FFA oxidation and thermogenesis [163].
All of these effects of leptin tend to limit further weight
gain.
Leptin resistance
As the process progresses, inefficient leptin action can lead
to the opposite of leptin's protective effects, e.g., hyper-
phagia, decreased fat oxidation, increased tissue TG levels,
insulin resistance, and overweight. Subsequently, plasma
leptin levels rise. The majority of obese individuals with
high leptin levels show a leptin insensitivity or "resistance
[164]," which occurs at the leptin receptor level. In animal
models, leptin-resistance and leptin-deficiency increases,
and upregulates the hepatic expression of SREBP-1c
mRNA, which may stimulate an increase in fat production
via de novo lipogenesis. Together, all of these features sug-
gest a state of "leptin resistance" which may ultimately
lead to obesity and metabolic syndrome [29,165].
It is quite possible that hyperleptinemia in diet-induced
obesity serves to protect nonadipose tissues (e.g. muscles,
liver, pancreatic β cells, and myocardium) from the toxic
effects resulting from the spillover of full adipose stores
and subsequent ectopic deposition of FFAs. In defense of
this paradigm, Unger points out that normally rats can
tolerate a 60 percent fat diet because 96 percent of the sur-
plus fat is stored in an enlarging adipose tissue mass, in
which leptin gene expression increases proportionally
[166]. However, when leptin is congenitally absent or
inactive, or ineffective due to resistance, even on a normal
or low-fat diet, excess dietary fat is deposited in nonadi-
pose tissues. This causes dysfunction (lipotoxicity), and
possible cell death (lipoaptosis) [29].Nutrition & Metabolism 2004, 1:12 http://www.nutritionandmetabolism.com/content/1/1/12
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Acquired leptin resistance occurs in aging, obesity, Cush-
ing's syndrome, and acquired lipodystrophy, a condition
associated with protease inhibitor therapy of AIDS. Pre-
liminary evidence suggests that patients with these condi-
tions have increased ectopic fat, i.e., lipid deposition in
non-adipose tissues [29].
Role of triglycerides in leptin resistance
The relation between cerebrospinal fluid and serum levels
of leptin in obese humans suggests that defective blood
brain barrier (BBB) transport accounts for a great deal of
leptin resistance in the CNS. Banks et al showed in mice
that serum TGs directly inhibit the transport of leptin
across the BBB and so could be a major cause of leptin
resistance across the central nervous system (CNS). Thus
they suggest that serum TGs are likely a major cause of the
leptin resistance seen in both obesity and starvation
[167]. This hypothesis explains why lowering TGs may be
therapeutically useful in enhancing the effects of leptin.
Implications for VAT in relative hypoleptinemia and metabolic 
syndrome
Compared to VAT, SCAT is the predominant source of lep-
tin [60], yet patients with VAT obesity may tend to have
higher leptin levels than normal, lean individuals but
lower than those with predominantly SCAT or subcutane-
ous obesity [29]. This suggests that the hyperleptinemia of
predominantly VAT obesity is not high enough to over-
come a leptin resistance due to the accumulation of
ectopic fat in nonadipose tissues, which leads to lipotox-
icity and ultimately the metabolic syndrome [29].
Lipodystrophies – A paradigm for the roles of fat depots and 
insufficient leptin action in metabolic syndrome
A number of clinical states exhibit evidence of leptin
insufficiency, either leptin deficiency or resistance, and
they all have in common the metabolic syndrome. These
include rare genetic diseases known as lipodystrophies,
which are characterized by a redistribution of fat. Ironi-
cally, in the more severe cases, e.g., congenital generalized
lipoatrophy, near-complete fat loss is associated with
severe insulin resistance, fatty liver, and classic features of
the metabolic syndrome. There is hyperleptinemia along
with hyperphagia and a predominance of intra-muscular
fat [168]. Dunnigan-type familial partial lipodystrophy is
a rare autosomal dominant condition characterized by
markedly reduced plasma leptin levels along with gradual
loss of SCAT from the extremities, trunk, and gluteal
region, commencing at the time of puberty, as well as
hyperinsulinemia, glucose intolerance, dyslipidemia
(high TGs with low HDL), and diabetes [169,170]. These
individuals do maintain central obesity and VAT [169],
which supports a relatively protective role for SCAT and
implicates VAT as being more pathogenic.
The aforementioned potential role of TGs in leptin resist-
ance may have implications for patients with lipodystro-
phy and lipoatrophy who have little or no fat mass, and as
a result, have very little or no leptin. They also have severe
hypertriglyceridemia that is reversed by treatment with
leptin [168,171]. The elevated plasma level of TGs in these
patients is likely inducing leptin resistance that is prevent-
ing the leptin from inducing TGs to be used as an energy
source. Thus the TGs in these patients are not oxidized,
and they are unable to settle into fat stores that would nor-
mally act as a TG sink and prevent their diversion to non-
adipose tissues where they contribute to lipotoxicity and
insulin resistance.
Fat depots can protect against lipotoxicity
Fat provides leptin and adiponectin
Transplantation of adipose tissue grafts in animal models
of congenital lipoatrophy reverses the signs of the meta-
bolic syndrome in a dose-dependent fashion [172]. Fur-
thermore, leptin treatment in humans and animals with
lipodystrophies also reverses fatty liver and insulin resist-
ance. However, transplantation of ob/ob adipose tissue
(which does not produce leptin) in lipodystrophic rats
does not reverse diabetes [173] nor is it beneficial to inject
leptin in obese humans with leptin resistance [18]. These
support the notion that insufficient leptin action may be
a cause of metabolic syndrome, and that adequate leptin
derived from SCAT is protective.
Like leptin, adiponectin secretion increases early on in
obesity and plays a role in reducing the expression of lipo-
genic enzymes and increases FA oxidation in peripheral
tissues thus limiting ectopic fat accumulation [174]. The
fact that adiponectin is secreted initially by fat but levels
are reduced as fat depots increase, may help resolve the
paradox of both lipodystrophy and obesity both being
insulin-resistant states [73].
Critical Visceral Adipose Tissue Threshold (CVATT) – 
Individual Variation
The CVATT has tremendous individual variation; thus a
relatively "thin" individual (with a normal BMI) and an
excess of VAT for him, may be metabolically obese, nor-
mal weight (MONW) [26]. Meanwhile, another individ-
ual with a large "pot belly" may have a great capacity to
store fat as SCAT with relatively little VAT or he may have
a high threshold for VAT. This may explain the finding
that while some individuals weighing even up to 200 kg
do not show any signs of type 2 diabetes or dyslipidemia,
while in others, diabetes or dyslipidemia either develop or
deteriorate with an increase in body weight of only one kg
[175] – perhaps just enough to exceed the CVATT.
A number of studies have looked at a possible CVATT
[176-182]. Using CT scans to measure VAT volume,Nutrition & Metabolism 2004, 1:12 http://www.nutritionandmetabolism.com/content/1/1/12
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Williams et al found that a value of above 110 cm2 was
associated with an increased risk of CHD in pre-and post-
menopausal women [177]. Similarly, Despres and
Lamarche observed a VAT cutoff of 100 cm2 was associ-
ated with increased CHD risk in young adult men and pre-
menopausal women (mostly of French Canadian descent)
[179], and a cutoff range of 100–110 cm2 has also been
observed by others [176,181]. Other studies have sug-
gested thresholds of > 130 cm2 for metabolic deterioration
[183,184]. De Nino et al found that insulin resistance did
not appear until women were older than 60 years and had
accumulated levels of VAT that approximated the levels
seen in men, suggesting a possible threshold effect of VAT
on insulin resistance [185]. As discussed below with
MONW, genetic and ethnic factors play a role. For exam-
ple, in nonobese and obese Japanese males and females,
fat areas at the umbilicus as determined by CT had thresh-
old values for metabolic syndrome with only > 100 cm2
for men and > 90 cm2 for women [186].
Brochu et al were unable to demonstrate that obese post-
menopausal women who reduced their weight and
attained a level of VAT below 110 cm2 would show greater
improvement in their metabolic profile compared to
those who also lost weight but remained above the 110
cm2 VAT threshold [178]. However, there were only 25
total subjects and the women had relatively normal meta-
bolic profiles at baseline. Perhaps due to the relatively
small number of subjects, only five lost less than 20 per-
cent of their baseline VAT value. Thus it is unclear whether
even smaller losses of VAT than those observed improved
metabolic outcomes. The researchers did find larger losses
of VAT and a greater improvement in insulin sensitivity in
those who attained a VAT level < 110 cm2 [178]. It should
also be noted that in postmenopausal women, peripheral
SCAT may be protective, even in the face of large amounts
of VAT, and this needs to be accounted for [120,121,125].
While studying obese Japanese women, Tanaka et al
recently validated the 100 cm2 CVATT but their longitudi-
nal data from both pre- and posttreatment suggest that
these women should reduce their VAT area to <60 cm2
through weight reduction to improve CHD risk factors
[181].
Metabolically obese normal weight (MONW)
VAT accumulation contributes to metabolic risk factors in
nonobese individuals [187,188]. Ruderman et al have
shown that normal weight individuals may also have
insulin resistance and the disorders of the metabolic syn-
drome [26]. They designated such individuals as "meta-
bolically obese normal weight – MONW [189,190]."
MONW subjects (BMI < 25 kg/m2) have been character-
ized by an excess of VAT area (> 100 cm2 by abdominal
CT), insulin resistance, and hyperinsulinemia [24-26]. As
pointed out earlier, the development of insulin resistance
may limit further weight gain [34,38-41,191]. A rapid and
early development of insulin resistance prior to significant
weight gain would explain that a significant number of
the normal-weight population have insulin resistance
[26]. The prevalence of MONW could be as high as 13 –
18 percent [26,192,193].
MONW and low birthweight
Both low birthweight (LBW) [194] and lowest weight at
one year of age have been linked to, VAT accumula-
tion[195] insulin resistance and cardiovascular risk fac-
tors in middle-aged and elderly individuals, many of
whom could be classified as MONW with metabolic syn-
drome. By middle age, many LBW subjects have BMIs less
than 24–26 kg/m2 and would be classified as MONW.
While some data suggest that LBW babies have central adi-
posity in middle age, definitive measurements of VAT in
these individuals are still lacking [26].
Ethnicity and MONW
One should consider ethnic differences when attempting
to identify MONW subjects. Lean appearing individuals,
especially in certain ethnic groups such as the Japanese,
may have significant amounts of VAT that surpass their
CVATT but appear with what, for the general population,
would be considered a normal BMI and waist circumfer-
ence [196]. For example, nonobese Japanese (BMI<25)
with increased VAT areas (100–110 cm2) fulfill the criteria
for MONW [25,181]. In another study, relatively lean Jap-
anese patients with newly diagnosed type 2 diabetes had
increased VAT. Through diet and without medication for
three months, the amount of VAT in these patients
became comparable to that in normal-weight control sub-
jects. Therefore, a three-month dietary treatment regimen
with small to moderate weight loss was very effective in
decreasing excess VAT in this population [197]. This illus-
trates the importance of early recognition of an individ-
ual's approaching or exceeding his CVATT. Park et al were
among the first to demonstrate that healthy, non-obese
Asian American women may have higher amounts of VAT,
and that normative values or standards for VAT derived
from Caucasians may not be applicable to Asians [196].
On the other side of the spectrum, a 10-year prospective
study studied increased BMI in Micronesian Nauruans (an
ethnic group from the central Pacific Ocean with rapidly
increase in prevalence of obesity) and Melanesian- and
Indian-Fijians. Overall, there was little evidence to suggest
that obesity was a risk factor for total or cardiovascular
mortality in these populations [198].
Metabolically normal obese (MNO)
McGarry found that one of his most obese patients in a
series (BMI 32.8 kg/m2) was one of the most insulin-sen-
sitive but had one of the lowest values for intramyocellu-
lar lipid (IMCL). Conversely, another subject, with a BMINutrition & Metabolism 2004, 1:12 http://www.nutritionandmetabolism.com/content/1/1/12
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of only 18.9 kg/m2, proved to be highly insulin-resistant
but had a large amount of IMCL. This supports that insu-
lin sensitivity appears to correlate more with where the fat
is located rather than the total amount in the body [42].
This has implications for the phenomena of the metabol-
ically obese normal weight (MONW) and the metaboli-
cally normal obese (MNO) individuals.
Like some of the Micronesian Nauruans and Indian-
Fijians above, there are individuals who are obese and
who nevertheless are metabolically normal – "metaboli-
cally normal obese; MNO." Unlike their MONW counter-
parts, MNO individuals have very little VAT
accumulation. They often share an onset of obesity early
in childhood, normal VAT, lower TGs, and increased
HDL. The actively competitive Japanese wrestlers main-
tain their gross obesity by consuming a 5,000 to 6,000 cal-
orie diet. They are MNO, and their VAT is normal in
amount, i.e., they have excessive amounts of SCAT [91].
On retirement, when they discontinue their rigorous
training regimen, they markedly develop increased insu-
lin resistance and metabolic syndrome. It is likely that that
their VAT increases concomitantly [26,27] and exceeds
their CVATT. Data from the European Group for the Study
of Insulin Resistance (1146 hyperinslinemic/euglycemic
clamp studies from 20 clinical centers in Europe) showed
that in "simple" obesity, insulin resistance is not as preva-
lent as previously thought [199]. MNO could account for
as much as 20 percent of the obese population [193]. In
another study using HOMA to determine insulin resist-
ance, Bonora et al showed that 11 percent of the entire
group of overweight individuals fit the criteria of MNO
[200]. Brochu et al extensively studied 43 sedentary,
obese, postmenopausal women and found that 17 were
MNO, while 26 had reduced insulin sensitivity (estimated
by clamp) [201]. The two groups were similar in total
body fat mass, SCAT amount, as well as waist circumfer-
ence, and total daily energy expenditure. However, lean
body mass was significantly greater in the metabolically
abnormal subjects. Unlike SCAT, VAT measured by CT
was inversely related to the insulin sensitivity and to a
classification of MNO. In fact, despite similar levels of
total body fatness, MNO individuals showed 49 percent
less VAT as measured by CT. However, the level of VAT
was still significant. Furthermore, using doubly labeled
water and indirect calorimetry, Brochu et al were unable
to demonstrate a meaningful difference between resting
metabolic rate and daily physical energy expenditure
between MNO and obese individuals at risk [201].
MNO and childhood obesity
Several investigators have found that there has been a pos-
itive association between insulin sensitivity and duration
of obesity, i.e., those who are obese since childhood are
more likely to remain insulin sensitive. In one study 48
percent of the MNO women presented with a history of an
earlier age-related onset of obesity (between 13 and 19
years of age) and less VAT compared with 29 percent of
the metabolically abnormal obese [201].
Insulin sensitivity seems to be dependent upon adipose
cell size; as adipocytes within tissue grow larger, they
become more insulin resistant [202]. Normal-sized, more
insulin-sensitive adipocytes have been associated with
early onset of obesity [203]. Perhaps today we are begin-
ning to see that with the marked increase in overfeeding
and extent of obesity at younger ages, hypertrophy of fat
cells may occur earlier and hence metabolic syndrome is
now occurring with greater frequency in children.
Puberty and VAT
During puberty, a certain degree of insulin resistance is
normal, and children who are more insulin resistant have
decreased SCAT fat gain [204]. Early in the development
of juvenile obesity, increased VAT, hyperinsulinemia, and
insulin resistance are closely linked [205]. Adrenal andro-
gens are elevated in obese children and have been associ-
ated with early pubertal development in these
children[206,207] Sex differences in VAT begin to emerge
during puberty, with boys having more VAT than girls.
Some studies suggest that the rate of VAT accumulation
can be slowed in children by using exercise interventions
[208,209].
Fit and fat
VAT is strongly associated with fitness even within indi-
viduals of the same weight. This is illustrated by the earlier
mentioned example of the active Sumo wrestler in his
prime who has relatively little VAT [91]. Regular exercise
can selectively reduce VAT with minimal change in weight
[210-212]. This could especially add to the frustration
level of the middle-aged or post-menopausal woman who
regularly exercises moderately without inducing measura-
ble reduction in body weight or fatness. She may still ben-
efit from reducing her VAT or attenuating the gain of VAT
"normally" experienced by sedentary women as they age.
It should be emphasized that the lower VAT level associ-
ated with increased fitness is modest but nonetheless clin-
ically important. Reduced morbidity is likely explained by
factors in addition to a reduced VAT, and VAT likely
explains morbidity independent of fitness [213]. Sumo
wrestlers tend to have most of their central adiposity
stored subcutaneously (as SCAT), and, perhaps a shift
toward more VAT accompanies their contracting meta-
bolic syndrome upon their retirement – with premature
death to follow [26,91]. This may also explain the body of
work showing that overweight or "fat" individuals who
are fit (according to cardiorespiratory testing on a tread-
mill) are at less risk for a cardiac event or developing type
2 diabetes than a "leaner" individual who is unfitNutrition & Metabolism 2004, 1:12 http://www.nutritionandmetabolism.com/content/1/1/12
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[214,215]. Thus, the former could be considered "fit and
fat." High levels of cardiorespiratory fitness (CRF) reduce
CRP and the rate of cardiovascular morbidity and mortal-
ity, independent of obesity [216]. CRF is also associated
with lower abdominal fat independent of BMI, and for a
given BMI or waist circumference (WC), individuals with
moderate CRF had lower levels of total fat mass and
abdominal SCAT and VAT than individuals with low CRF
for a given BMI or WC value [213,217]. Low CRF is an
independent risk factor for mortality in healthy-appearing
and diseased populations, and is associated with elevated
CRP and reduced fasting glucose control in women with
type 2 diabetes [218]. It is likely that compared to the fit
and fat, the unfit and lean-appearing individual may have
greater amounts of "hidden" VAT.
Effects of exercise
In obese patients, increasing physical activity can enhance
fat oxidation, reduce IMCL and improve insulin sensitiv-
ity [219]. Exercise training may reduce waist size, inde-
pendent of changes in BMI, and exercise without weight
loss is effective in reducing VAT and preventing further
increases in obesity [213,220].
Ross et al showed that either modality, caloric restriction
alone or daily exercise without calorie restriction, is an
effective strategy for reducing obesity in moderately obese
men.
Their findings also suggest that exercise without weight
loss is a useful method for reducing VAT and preventing
further increases in obesity [220]. Irwin et al studied 168
overweight, postmenopausal, previously sedentary
women in a randomly controlled trial of exercise versus
no exercise. While the body weight lost at 12 months
among the exercisers was modest, the amount of intra-
abdominal fat lost was considerable (8.5 g/ cm2) and was
dose-dependent. The women who exercised for approxi-
mately 200 min/wk lost 4.2 percent of total body fat and
6.9 percent of VAT without reducing their energy intake
[212]. Exercise may counteract the abnormal metabolic
profiles associated with abdominal obesity by reducing
VAT along with other independent mechanisms. It pro-
motes adaptive responses including those causing mus-
cles to increase their use of lipid stores rather than relying
primarily on carbohydrate reserves. Even a single bout of
exercise can reduce triglyceride levels, increase HDL levels,
reduce resting blood pressure, increase glucose tolerance,
and reduce insulin resistance [221].
While evidence supports that CRF may be associated with
a lower VAT, this is certainly not proven. However, study
results suggest that individuals with moderate to high CRF
levels have lower WC than men with low CRF independ-
ent of BMI [213,222]. Data support that the substantial
reductions in health risk often associated with modest
weight loss (<10 percent) may be mediated in part by a
preferential reduction in VAT [48,216,217,220,223]. This
is reinforced by the finding that reductions in VAT alone
were related to improvements in glucose tolerance and
insulin sensitivity [220,224]. Therefore, it would seem
reasonable to infer that the combination of high CRF and
low abdominal fat, especially VAT, would be associated
with reductions in metabolic risk compared with those
with the same BMI, but low CRF and high VAT [213]. Add-
ing resistance training to aerobic exercise may add to an
improvement in insulin sensitivity related to a loss of VAT
and an increase in muscle density [225,226].
Surgical Interventions Shed Light on Pathophysiology
Surgical removal of VAT in animals and humans dramati-
cally improves insulin resistance and diabetes. In a Swed-
ish, single-center, randomized and controlled pilot trial of
50 severely obese adults, Thorne et al compared 25
patients who underwent adjustable gastric banding (AGB)
alone with AGB plus surgical removal of the total greater
omentum. At two-year follow-up there were no statistical
differences between groups with regard to weight loss,
changes in WHR or sagittal diameter. However, the
improvements in oral glucose tolerance insulin sensitivity
and fasting plasma glucose and insulin were 2–3 times
greater in omentectomized as compared to control sub-
jects, which was statistically independent of the loss in
BMI [52]. More recently, this has led to a study of another
experimental procedure performed by surgeons at Bos-
ton's Beth Israel Deaconess Medical Center working in
conjunction with Joslin Diabetes Center. Using a two-
hour laparoscopic procedure that involves extracting
strips of only the omentum through tiny incisions, this
will be the first study to examine the possible health ben-
efits of removing only the omentum [227].
Recently Klein et al. demonstrated that liposuction con-
ferred no benefits with regard to metabolic profile [53].
Furthermore, Weber et al showed that after 3 months, ani-
mals that had lipectomy of > 50 percent of SCAT had
more intra-abdominal VAT as percentage of total body fat,
higher insulinemic index, a strong trend toward increased
liver fat content, and markedly elevated serum TGs com-
pared with animals that had undergone a sham operation
and received either a high- or low-fat diet [228]. Together
with the findings above, these support a pathologic role
for VAT and a possible protective role for SCAT. Removing
SCAT might actually increase risk as one removes a buffer
or sink for peripheral TGs [228].
Environmental Considerations
Organochlorines, adipose tissue, and energy balance
Since our genes have not changed significantly in the past
10,000 years, the rise in obesity can be attributed to theNutrition & Metabolism 2004, 1:12 http://www.nutritionandmetabolism.com/content/1/1/12
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environment, including what we are exposed to in the way
of food as well as the level of physical activity. While the
main focus has been on diet and activity, what may be
overlooked is the tremendous increase in exposure to syn-
thetic organic and inorganic chemicals, which can damage
many of the mechanisms involved in weight control.
Most of us have been exposed to organochlorines found
in pesticides, dyes, solvents, etc., and we contain residues
in our adipose tissue, where they are preferentially stored.
Thus, the obese tend to have increased organochlorine
concentrations compared to lean individuals [229]. Dur-
ing body weight loss, a decrease in fat mass results in lipid
mobilization, and organochlorine concentrations
increase both in plasma and remaining adipose tissue.
Even after adjustment for weight loss, the related increase
in organochlorine concentration has been correlated with
decreases in triidothyronine (T3) concentration and rest-
ing metabolic rate [230]. This is also associated with a
reduction in activity of the skeletal muscle oxidative
enzymes that normally are involved in fat oxidation
[231]. The net effect could prevent further weight gain and
might even encourage weight regain beyond the initial
baseline [232], which could contribute to VAT.
Implications of Controlling Dietary Carbohydrates
Reduced fat oxidation and carbohydrates
Frisancho points out that an important contributing fac-
tor for obesity in modern as well as developing nations is
a reduced fat oxidation and increased metabolism of car-
bohydrate. This has been brought about by a shift toward
the body's preference toward oxidizing carbohydrate
rather than fat – resulting in an increased deposition of
body fat. In developing nations, obesity can co-exist with
developmental undernutrition, which can result in obes-
ity with short stature [233].
A solution to reducing the ectopic fat, as well as VAT, bur-
den would be to enhance its oxidation in nonadipose tis-
sues, e.g., liver, pancreas, and skeletal muscle. This will
push the system toward below the CVATT and improve
insulin sensitivity. In their review, Westman et al cite
many studies that have consistently shown that low-car-
bohydrate/high-fat diets consumed for more than seven
days induce powerful metabolic adaptations to enhance
fat oxidation [37]. Such diets will reduce muscle glycogen
content and carbohydrate oxidation, even in well-trained
athletes who already demonstrate increased oxidation
[37,154]. The authors' paradigm suggests that, under
these conditions, insulin resistance could improve by
reducing glucose appearance and cellular influx, resulting
in a preferential fat oxidation and protection against lipo-
toxicity. In an elegant study, Bisschop et al support this by
showing that high-fat, low-carbohydrate diets do not
affect the action of insulin on total glucose disposal but
decrease basal endogenous glucose production and
improve insulin-stimulated nonoxidative glucose dis-
posal [234]. Sharman et al demonstrated short term
improvements of a ketogenic diet on lipids in normal
weight men. These benefits occurred without total weight
loss but there was evidence of a change in body composi-
tion toward more lean body mass [235]. One would also
expect a reduction in VAT as he moves to the left or below
his CVATT (See figure 1). Weight loss does not appear to
be necessary to reduce mortality rates in overweight or
obese men who increase their aerobic fitness or level of
physical activity [224]. Similarly, in overweight, postmen-
opausal women, exercise may lead to improved metabolic
profiles and VAT loss without total weight loss [212].
Dietary carbohydrate and VAT
Optimizing macronutrients and food preparation can
have beneficial effects in those with visceral obesity. A
number of recent reviews support the metabolic benefits
of controlling glycemic index (GI) [236] and glycemic
load (GL) [237]. In a 12-month pilot study of teens, com-
pared to a conventional diet, a lower GI diet led to greater
total weight and fat loss without regain from months 6–
12. While insulin resistance as measured by HOMA
increased in the conventional group (possibly in part
attributable to puberty), the lower GI group showed no
change [238]. Recently, Silvestre et al showed that com-
pared to an energy-restricted low-fat diet, a short-term,
very low-carbohydrate diet was associated with greater
weight and fat loss with an apparent preferential loss of
central fat [239].
VAT cells have a two-fold higher glucose uptake rate com-
pared with SCAT cells [87]. It may follow that reducing
glucose exposure by reducing glycemic load may reduce
the supply of glucose to the VAT depot and possibly
impair its accumulation. Glucose raises insulin concentra-
tion, which can stimulate 11-β-HSD1, increase active cor-
tisol in VAT, and enhance VAT accumulation [102].
Feeding rats a high-GI starch diet over five weeks resulted
in higher VAT and larger adipocyte volume than did feed-
ing low-GI starch ad libitum. Replacing this with a low-GI
starch diet increased insulin -stimulated glucose oxida-
tion, decreased glucose incorporation into total lipids and
decreased VAT adipocyte diameter [240,241]. Together,
these add to the evidence supporting the benefits of low-
ering GI to reduce and maintain lower volumes of VAT.
Feeding rats a high sucrose diet increases both VAT and
muscle insulin resistance [242]. Keno et al. demonstrated
in rats that a high sucrose diet compared to a lab chow
diet led to a significantly greater fat cell volume in VAT
depots [243]. Although fat cell number did not change,
the ratio of VAT weight to SCAT weight was also signifi-
cantly increased in the rats fed a high sucrose diet, provid-
ing further evidence for controlling the dietary GI and GL.Nutrition & Metabolism 2004, 1:12 http://www.nutritionandmetabolism.com/content/1/1/12
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A number of studies have demonstrated an association
between glycemic load (GL) and levels of CRP [244,245],
which is a powerful predictor for diabetes and CHD, and
is positively associated with both insulin resistance and
the prevalence of the metabolic syndrome [246]. O'Brien
et al showed that compared to a high carbohydrate diet, a
low carbohydrate diet reduced SAA and CRP, both mark-
ers of inflammation and risk factors for metabolic syn-
drome [247]. Relative to fat (cream) and protein (casein),
a glucose challenge elicits the greatest production of radi-
cal oxygen species (ROS) by polymorphonuclear and
mononuclear white cells [248,249]. Chronic carbohy-
drate ingestion with a high GL diet can lead to hyperin-
sulinemia, as well as hypertrophy, functional
dysregulation, and overresponsiveness of the pancreatic β
cell and hepatic production of newly synthesized fatty
acids via de novo lipogenesis [43]. A Johns Hopkins study
examined intra-operative liver biopsies obtained from 74
consecutive morbidly obese patients undergoing bariatric
surgery. Compared with patients with the lowest carbohy-
drate intake [246], a high-carbohydrate diet was associ-
ated with an odds ratio of 7.0 for liver inflammation. A
high fat diet appeared to be protective, with those in the
highest fat intake group having an OR of 0.17 [250]. This
is consistent with the findings of others who found that
dietary fat explained only two percent of the variance in
general adiposity and dietary fat appears to play only a
minor role in determining general adiposity and is not
related to VAT when measured in cross-sectional studies
[251]. Apparently, GL may be more significant in this
regard.
Compared to SCAT, VAT (both adipose and non-adipose
cells within VAT) is associated more with PAI-1 – a pow-
erful risk factor for CHD [58,252]. In patients with type 2
diabetes, a simple and modest lowering of the GI com-
pared to an otherwise similar diet led to dramatic changes:
a normalized PAI-1 activity (-54 percent, P < 0.001) as
well as lowering of both blood glucose and plasma insulin
concentrations by 30 percent, and a 29 percent decrease in
LDL-C [253]. All subjects began with a BMI < 27, and
there was only a slight but similar weight loss in both
groups over the 24 days. The results support the potential
benefit of lowering dietary GI in patients with metabolic
syndrome, especially those with VAT and elevated PAI-1.
This is also supported by the observation of hyperglyc-
emia induces PAI-1 gene expression in adipose tissue of
rats [254].
Esposito et al demonstrated in both diabetics and non-
diabetics that after consuming a high carbohydrate high-
fiber meal, IL-18 (a potent pro-inflammatory cytokine)
concentrations increased [49]. Adiponectin concentra-
tions decreased after the high-carbohydrate, low-fiber
meal in diabetic patients. The fiber content of complex
carbohydrates seemed to affect circulating IL-18 and adi-
ponectin concentrations in response to the same carbohy-
drate load. The pizza that was made with whole flour and
was rich in fiber was associated with reduce serum IL-18
concentrations and unchanged serum adiponectin con-
centrations. Meanwhile, the pizza prepared with refined
flour and was low in fiber raised circulating IL-18 concen-
trations. Serum glucose and TG concentrations were not
significantly different between the two types of pizza. The
study did not completely resolve the mechanism by which
the fiber content of meals influences IL-18 and adiponec-
tin. However, it appears that while the GL of each pizza
was the same, the GI of the whole wheat pizza would be
much less and may be more beneficial.
Recently, dietary TGs have been demonstrated to contrib-
ute to CNS leptin resistance by impairing the transport of
leptin across the blood brain barrier where it would usu-
ally stimulate the release of neuropeptide-Y and reduce
feeding behavior [167]. Reducing dietary carbohydrates
lowers serum TGs, which theoretically should protect
against this form of leptin resistance [167].
Dietary influences on leptin action
Leptin may enhance fatty acid oxidation and protects
against fat deposition and lipotoxicity. As mentioned ear-
lier, normally, rats can tolerate a 60 percent fat diet
because 96 percent of the surplus fat is stored in an enlarg-
ing adipose tissue mass, in which leptin gene expression
increases proportionally [166]. However, when leptin is
congenitally absent or inactive, or ineffective due to resist-
ance, even on a normal or low-fat diet, unutilized dietary
fat is deposited in nonadipose tissues, causing dysfunc-
tion (lipotoxicity), and possible cell death (lipoaptosis)
[29].
Acute overfeeding can cause circulating leptin levels to rise
by 40 percent and more than three-fold after chronic over-
feeding, whereas fasting is associated with a decreased lep-
tin levels. This may suggest that overfeeding leads to leptin
resistance. Dietary carbohydrates may influence leptin
action. Some investigators have suggested that the
increase in plasma leptin concentration observed after
meals is not simply a result of an energy load but is in
response to a signal that is not present following a fat load
without carbohydrate [157]. SCAT-derived leptin (which
circulates in a free form and is bound to a soluble leptin
receptor – sOB-R) plays a key role in regulating energy
homeostasis and metabolism, sOB-R is positively associ-
ated with energy intake from carbohydrates and nega-
tively associated with energy intake from dietary fat [158].
While this suggests that dietary fat and carbohydrates reg-
ulate free leptin levels, the implications of this are not yet
completely clear.Nutrition & Metabolism 2004, 1:12 http://www.nutritionandmetabolism.com/content/1/1/12
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Stress
There is an association with lifestyle, worry, cortisol levels,
and abdominal girth. Those who were found to have the
highest levels of chronic stress had the highest levels of
cortisol and VAT [255-257]. This is supported by evidence
that a number of medications, including prednisone, may
cause an excess of cortisol and insulin resistance. Taken
orally, cortisol raises blood pressure, and it has been
shown to impair brachial artery blood flow in response to
an acetylcholine challenge, i.e., an indicator of endothe-
lial dysfunction [88,255,257-262]. Even brief episodes of
mental stress, such as those encountered in daily life, may
cause transient endothelial dysfunction even in young,
healthy individuals ([263,264]. In turn, subsequent
cytokine release may increase anxiety and have negative
effects on emotional and memory functions [265]. Psy-
chological stress has also been demonstrated to acutely
reduce clearance of triglycerides [266], which could con-
tribute to CNS leptin resistance [167].
There are many other ways in which psychological stress
might increase the likelihood of developing metabolic
syndrome and type 2 diabetes, for example, chronic psy-
chological stress may also be related to central activation
of the HPA (hypothalamo-pituitary-adrenal) axis and the
sympathetic nervous system (SNS) [267]. Psychological
stress also induces IL-6, TNFα, and other cytokine secre-
tions from macrophages [267-271]. Repeated stress with
the repeated induction of corticosteroids can damage the
hippocampus, which is involved in the downregulation of
corticosteroid production by corticosteroid feedback.
Impairment of this feedback mechanism can lead to
persisting elevated circulating cortisol levels [267], which
might play a role in inducing VAT accumulation.
This diagram provides an overview of how behavioral and environmental factors can lead to VAT obesity and, ultimately, met- abolic syndrome and related disorders Figure 3
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Stress decreases splanchnic blood flow, impairs the integ-
rity of the GI tract, increases intestinal permeability, and
results in increased absorption of lipopolysaccharide
endotoxin (LPS) from the gut (the greatest source of LPS).
Elevated portal bloodstream LPS levels stimulate Kupffer
cell receptors and cytokine release and possibly other
immune-challenging activators, e.g., AGEs in food [271].
Stress and dietary carbohydrates
Dietary carbohydrate has been known to stimulate SNS
activity though a number of studies have emphasized the
role of insulin. Recent studies in rats have demonstrated
that adding glucose to the basic diet increased SNS activity
in peripheral tissues and increased GLUT 4 activity in
interscapular brown adipose tissue and retroperitoneal fat
(but not in epididymal fat) [272]. Overfeeding results in
high insulin levels. In the presence of glucose, insulin acts
on the brain to increase the SNS tone, which, in turn
enhances thermogenesis and dissipation of excess calories
[163]. There is a close relationship between postprandial
insulinemia, SNS activation, and adipose tissue blood
flow (ATBF). ATBF increases in response to stress states
such as exercise or mental stress, and also in response to
nutrient intake [273]. High insulin levels and increased
SNS tone are useful for the maintenance of caloric bal-
ance, but in the long term they are conducive to CHD,
hypertension, sudden death, and obesity as the SNS recep-
tors become down regulated [163].
Chronic stress leads to elevated cortisol levels, which may
lead to accumulation of VAT and metabolic syndrome
[274]. Stress-induced increased levels of glucocorticoids
can also have a major effect on food intake [275]. A subset
of stressed or depressed humans may overeat, especially
comfort food (e.g., sugar and fat), in an attempt to reduce
anxiety and activity in the chronic stress-response net-
work. This is supported by the finding that these people
have decreased cerebrospinal corticosteroid releasing fac-
tor, catecholamine concentrations, and HPA activity.
While comfort foods may calm them down in the short
term, they may lead to abdominal obesity if this becomes
a long term "solution." The chronic elevation of systemic
glucocorticoids may contribute to VAT deposition. By
itself, being obese may be a stressful stimulus to overeat-
ing. A weight loss program can be stressful, which can sab-
otage its success by eliciting the release of stress
hormones, which, in turn can make a person crave high
energy foods [275]. Feeding rats a long-term high-sucrose
diet along with supplemental dexamethasone has been
shown to increase fat depots and induce liver steatosis
[276]. In addition to dietary intervention, stress manage-
ment may improve one's cognitive, behavioral, and phys-
iologic responses to stress, including glycemia [277].
Summary
The role of visceral adipose tissue (VAT) obesity in meta-
bolic syndrome is critical and complex. (See figure 3). The
paradigm of an individual critical VAT threshold (CVATT)
has been presented along with a review of potential mech-
anisms and contributing factors. This includes the poten-
tial role of dietary carbohydrates in VAT obesity. As this
area continues to evolve, perhaps the reviewed material
and proposed concepts may have relevance to clinical
assessment, prevention, and treatment of metabolic
syndrome.
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